Part I: Pharmacoeconomic evaluation (20marks)
Sample case :
A tertiary care hospital in UAE needs to decide if it should addlow molecular weight heparin (Dalteparin) to the formulary, whichis therapeutically equivalent to the currently used Unfractionatedheparin (UFH). The hospital treats patients with deepvein thrombosis and other cases of thrombosis. The major advantageof Dalteparin is that it only has to be administered once per dayversus multiple times a day for UFH. Though the side effect profilevaries, it can be prevented with proper INR monitoring.
Instructions to students:
Select a suitable pharmacoeconomic method and perform comparingadministration of Clexane with UFH for patients with deep veinthrombosis. Follow all the seven steps givenbelow.
Step 1: Define the problem (1m)
______________________________________________________________________________
Step 2: Determine the study’s perspective (1m)
______________________________________________________________________________
Step 3: Determine specific treatment alternatives and outcomes(1m)
______________________________________________________________________________
Step 4: Select the appropriate pharmacoeconomic method or model(1m)
______________________________________________________________________________
Step 5: Measure inputs and outcomes (1m)
______________________________________________________________________________
Step 6: Identify the resources necessary to conduct the analysis(1m)
______________________________________________________________________________
______________________________________________________________________________
Step 7: Present the results (4 m)
[Present in Table form]
Recommendations to the formulary committee:
[Here just mention whether Clexane should be added or now in theformulary]
